PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors

被引：4

作者：

Ellingson, Benjamin M. ^{[1
,2
,3
]}

Chen, Wei ^{[4
]}

Harris, Robert J. ^{[1
,2
]}

Pope, Whitney B. ^{[1
]}

Lai, Albert ^{[5
]}

Nghiemphu, Phioanh L. ^{[5
]}

Czernin, Johannes ^{[4
]}

Phelps, Michael E. ^{[4
]}

Cloughesy, Timothy F. ^{[5
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, 924 Westwood Blvd,Suite 615, Los Angeles, CA 90024 USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomed Phys, Los Angeles, CA 90024 USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomed Engn, Los Angeles, CA 90024 USA

[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA

[5] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA

来源：

PET CLINICS | 2013年 / 8卷 / 02期

关键词：

PET; PET parametric response maps; Glioblastoma; GBM; Brain tumors; Imaging; Response; Biomarker;

D O I：

10.1016/j.cpet.2012.09.002

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

PET parametric response maps (PRMs) are a provocative new molecular imaging technique for quantifying brain tumor response to therapy in individual patients. By aligning sequential PET scans over time using anatomic MR imaging information, the voxel-wise change in radiotracer uptake can be quantified and visualized. PET PRMs can be performed before and after a particular therapy to test whether the tumor is responding favorably, or performed relative to a distant time point to monitor changes through the course of a treatment. This article focuses on many of the technical details involved in generating, visualizing, and quantifying PET PRMs, and practical applications and example case studies.

引用

页码：201 / +

页数：18

共 79 条

[1]

[Anonymous], 2010, PRIM BRA CTR NERV SY

[2] Noninvasive quantification of 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma [J].

Backes, Heiko ;

Ullrich, Roland ;

Neumaier, Bernd ;

Kracht, Lutz ;

Wienhard, Klaus ;

Jacobs, Andreas H. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (12) :1960-1967

[3] Brain tumour imaging with PET:: a comparison between [18F]fluorodopa and [11C]methionine [J].

Becherer, A ;

Karanikas, G ;

Szabó, M ;

Zettinig, G ;

Asenbaum, S ;

Marosi, C ;

Henk, C ;

Wunderbaldinger, P ;

Czech, T ;

Wadsak, W ;

Kletter, K .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (11) :1561-1567

[4] DISCREPANCIES IN BRAIN-TUMOR EXTENT AS SHOWN BY COMPUTED-TOMOGRAPHY AND POSITRON EMISSION TOMOGRAPHY USING [GA-68] EDTA, [C-11] GLUCOSE, AND [C-11] METHIONINE [J].

BERGSTROM, M ;

COLLINS, VP ;

EHRIN, E ;

ERICSON, K ;

ERIKSSON, L ;

GREITZ, T ;

HALLDIN, C ;

VONHOLST, H ;

LANGSTROM, B ;

LILJA, A ;

LUNDQVIST, H ;

NAGREN, K .

JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1983, 7 (06) :1062-1066

[5] 3-O-Methyl-6-[18F]fluoro-L-DOPA and its evaluation in brain tumour imaging [J].

Beuthien-Baumann, B ;

Bredow, J ;

Burchert, W ;

Füchtner, F ;

Bergmann, R ;

Alheit, HD ;

Reiss, G ;

Hliscs, R ;

Steinmeier, R ;

Franke, WG ;

Johannsen, B ;

Kotzerke, J .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (07) :1004-1008

[6] Therapeutic targets in radiotherapy [J].

Brown, JM .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (02) :319-326

[7]

BUSCH H, 1959, CANCER RES, V19, P1030

[8]

Chen W, 2005, J NUCL MED, V46, P945

[9]

CHIANG PK, 1977, J BIOL CHEM, V252, P4506

[10] FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan [J].

Colavolpe, Cecile ;

Chinot, Olivier ;

Metellus, Philippe ;

Mancini, Julien ;

Barrie, Maryline ;

Bequet-Boucard, Celine ;

Tabouret, Emeline ;

Mundler, Olivier ;

Figarella-Branger, Dominique ;

Guedj, Eric .

NEURO-ONCOLOGY, 2012, 14 (05) :649-657

← 1 2 3 4 5 6 7 8 →